Despite the equivocal reports in the mainstream media of the recently released omega-3s trials, the huge statistical power of the studies means the promising secondary endpoints can be trusted, experts say.
Dietary supplements have held out the promise of greater health. Has the category delivered on that promise? Are people healthier now than they were decades ago?
Krill-derived omega-3 fatty acids appear to reduce fasting levels of blood glucose, a Rimfrost-funded study finds, as researchers point to its supplementation as an effective approach in reducing cardiovascular disease (CVD) risk.
Amarin Corporation, maker of EPA drug Vascepa, has sued two omega-3s finished good manufacturers for unfair trade practices for allegedly using the results of the company’s large scale drug trial to market their own fish-oil based dietary supplements.
GOED has clarified what method should be used by member companies to calculate the EPA and DHA content of their products to avoid confusion for consumers.
You’ve heard of EPA and DHA omega-3, but what about ETA? A new study from Canada indicates that ETA (eicosatetraenoic acid, 20:4) may convert into two novel compounds associated with inflammation management.
A population study conducted on a cohort living in Boston has found an association of higher blood levels of omega-3s with better executive function in older individuals. The researchers also found negative connotations with higher omega-6 levels.
Researchers in Australia found that pre-menopausal women supplemented with 1 g of DHA-rich tuna oil had significantly lowered triglyceride levels compared to those who took the placebo.
A review conducted by researchers in New York uncovered six potential modes of action for how omega-3s might alleviate symptoms of anxiety. But the researchers found lots of nits to pick with the research, too, and made recommendations for future studies...
French microalgae firm Fermentalg and Madrid-based fermentation specialist ADL BioPharma have signed a long-term manufacturing contract for the production of algal omega-3 oils.
Results from an omega-3 study found a positive link between treatment using EPA and cardiovascular outcomes. It was backed by pharmaceutical company Amarin, which enjoyed a 300% surge in shares after the study results were announced.
